<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: The study of incidence of clinico-laboratory signs of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APLS) and the results of its treatment in SLE </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIALS AND METHODS: Out of 120 patients with verified SLE, 13 (10.8%) had the signs of APLS </plain></SENT>
<SENT sid="2" pm="."><plain>They underwent additional tests (platelet and <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> blood <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> assays, assessment of immunity) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: APLS treatment consisted of suppression of <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> production by glucocorticosteroids and <z:chebi fb="0" ids="35610">cytostatics</z:chebi>, removal of antibodies by means of plasmapheresis, HBO therapy of thromboses and vascular defects </plain></SENT>
<SENT sid="4" pm="."><plain>APLS in SLE frequently manifested with arterial thromboses, cerebrovasculitis, livedo, <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo>, <z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: Combined treatment of APLS in SLE improves the disease prognosis and prolongs life span </plain></SENT>
</text></document>